Magenta Therapeutics
Edit info- Founded: 2016
- Location: Cambridge, MA
- Employee range: 50 - 200
- Funding: $100M IPO Jun 2018
magentatx.com linkedin.com job board
Business:
Stem Cell, Bone Marrow Transplant Technology
About:
Magenta Therapeutics is using the curative power of stem cell transplants to treat patients with genetic and autoimmune diseases. Stem cell transplants involve three main steps: (i) mobilization and collection of stem cells from patients’ bone marrow, (ii) conditioning, to remove patients’ stem cells to make space for new ones and (iii) transplantation and engraftment of healthy stem cells to restore the immune and blood system free of disease. Magenta is developing programs to enhance the first two steps of stem cell mobilization involving small molecule and antibody-drug conjugate identification. Clinical progress has been made with MGTA-145 to mobilize and collect stem cells in multiple myeloma patients.
Jobs:
News:
Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors - Business Wire
googlenews
Jan 9, 2023
New hires
external-link
Days after halting leukemia drug, Magenta moves to close its doors - Fierce Biotech
googlenews
Feb 2, 2023
Science/business updates
external-link
Magenta halts high-dose group in leukemia trial after serious adverse events - Fierce Biotech
googlenews
Dec 20, 2022
Science/business updates
external-link
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
crunchbase
Oct 4, 2021
New hires
external-link
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors - Business Wire
googlenews
May 12, 2021
Funding-related
external-link
Vividion Therapeutics Names Shawn Rose as Chief Development Officer - Business Wire
googlenews
Sep 7, 2023
New hires
external-link
Compositions and methods for the depletion of cd117+ cells
crunchbase
Apr 4, 2024
Science/business updates
external-link
Magenta halts study of targeted conditioning drug after participant’s death - BioPharma Dive
googlenews
Jan 26, 2023
Science/business updates
external-link
Digital health startups worth $7.6 billion are set to IPO, breaking a 3-year drought. Here's what 5 top VCs are keeping an eye on.
crunchbase
May 14, 2019
Funding-related
external-link
Tackling blood diseases, immune disorders - Harvard Gazette
googlenews
Nov 16, 2016
Science/business updates
external-link
Compositions and methods for treating hematological malignancies
crunchbase
Feb 15, 2023
Science/business updates
external-link
Magenta agrees to reverse merger with Dianthus after setbacks - BioPharma Dive
googlenews
May 3, 2023
Science/business updates
external-link
Days after halting leukemia drug, Magenta moves to close ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
Why The Magenta Therapeutics (MGTA) Stock Increased 4.55%
crunchbase
Dec 12, 2022
Science/business updates
external-link
Magenta Therapeutics appoints new Chief People Officer - People Matters
googlenews
Feb 13, 2020
New hires
external-link
Magenta eyes $100M IPO to help ‘lead a new era in transplant medicine’
crunchbase
May 25, 2018
Funding-related
external-link
Another setback for Magenta Therapeutics’ MGTA-117 - The Pharma Letter
googlenews
Jan 26, 2023
Science/business updates
external-link
Magenta hoists Dianthus onto its shoulders via reverse merger - Fierce Biotech
googlenews
May 3, 2023
Funding-related
external-link
StockWatch: Patient Death Rattles Magenta Therapeutics, Analysts
crunchbase
Jan 26, 2023
Science/business updates
external-link
Magenta Therapeutics: Potential Upside In The Merger, Wait To Buy More (MGTA) - Seeking Alpha
googlenews
Jul 28, 2023
Science/business updates
external-link
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase - GlobeNewswire
googlenews
Jan 25, 2023
Science/business updates
external-link
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
crunchbase
Dec 21, 2022
Science/business updates
external-link
UPDATE: Magenta cuts 14% of staff, trims R&D amid ...
fiercebiotech.com
Dec 19, 2024
New hires
external-link
Magenta Therapeutics to shut down after patient death
crunchbase
Feb 3, 2023
Science/business updates
external-link
Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
crunchbase
Feb 21, 2019
Science/business updates
external-link
Magenta CEO exits, 84% of staff let go as shuttering looms
crunchbase
Feb 9, 2023
Science/business updates
external-link
Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
crunchbase
Jul 20, 2022
Science/business updates
external-link
Magenta's C-suite heads out the door with 85% of staff
fiercebiotech.com
Dec 19, 2024
New hires
external-link
Magenta Therapeutics and Dianthus Therapeutics to Merge - citybiz
googlenews
May 4, 2023
Science/business updates
external-link
Methods and compositions for treating autoimmune diseases
crunchbase
Dec 3, 2021
Science/business updates
external-link
StockWatch: Patient Death Rattles Magenta Therapeutics, Analysts - Genetic Engineering & Biotechnology News
googlenews
Jan 26, 2023
Science/business updates
external-link
Patient Death Pauses Another AML Trial - BioSpace
googlenews
Jan 26, 2023
Science/business updates
external-link
Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option to Further Develop Antibody Targeted Amanitin Conjugates Targeted to CD45
crunchbase
Nov 11, 2019
Science/business updates
external-link
Magenta Enters Collaboration Agreement with Beam to Further Explore MGTA-117
crunchbase
Jun 15, 2020
Science/business updates
external-link
Here's What Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shareholder Ownership Structure Looks Like
crunchbase
Aug 4, 2020
Funding-related
external-link
Magenta Therapeutics' research lead Davis hits the exit for ...
fiercebiotech.com
Dec 19, 2024
New hires
external-link
Magenta Therapeutics Announces Pricing of Public Offering
crunchbase
Jun 24, 2020
Funding-related
external-link
Why The Magenta Therapeutics Stock Fell 11.09% (MGTA)
crunchbase
Jan 27, 2023
Science/business updates
external-link
Anti-CD45 Antibody Drug Conjugates and Uses Thereof
crunchbase
Oct 22, 2021
Science/business updates
external-link
Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug
crunchbase
Jul 21, 2021
Science/business updates
external-link
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
crunchbase
Jul 6, 2021
New hires
external-link
Patient death spurs trial halt for Magenta Therapeutics
crunchbase
Jan 26, 2023
Science/business updates
external-link
Magenta Therapeutics Secures $52 Million in Series C Financing
crunchbase
Apr 10, 2018
Funding-related
external-link
After dose de-escalation, death drives Magenta to pause ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
Magenta Therapeutics Stock (MGTA): Why The Price Jumped Today
crunchbase
Jan 7, 2022
Science/business updates
external-link
Another setback for Magenta Therapeutics’ MGTA-117
crunchbase
Jan 26, 2023
Science/business updates
external-link
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
crunchbase
Aug 17, 2022
New hires
external-link
Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai?
crunchbase
Feb 3, 2023
Funding-related
external-link
Dosing regimens for the mobilization of hematopoietic stem cells
crunchbase
May 12, 2022
Science/business updates
external-link
Anti-cd117 antibody drug conjugates and uses thereof
crunchbase
Oct 22, 2021
Science/business updates
external-link
Chutes & Ladders—3 Flagship-backed biotechs make key exec hires - Fierce Biotech
googlenews
Aug 18, 2023
New hires
external-link
Compositions and methods for allogeneic transplantation
crunchbase
Aug 17, 2022
Science/business updates
external-link
Avrobio And Magenta Therapeutics Collaborate - Contract Pharma
googlenews
Jun 5, 2020
Science/business updates
external-link
Viridian inks $185M financing, hires three Magenta executives as CEO Scott Myers exits - Endpoints News
googlenews
Oct 30, 2023
Funding-related
external-link
Magenta halts group in leukemia trial after serious side ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
Dianthus Therapeutics Appoints Adam Veness, Esq., as General Counsel - PR Newswire
googlenews
Jun 20, 2023
New hires
external-link
Magenta poaches Constellation CMO Humphrey after 5 ...
fiercebiotech.com
Dec 20, 2024
New hires
external-link
Semma names former Novartis, Magenta executive as new CEO
crunchbase
May 10, 2018
New hires
external-link
Magenta's C-suite heads out the door with 85% of staff as closing process gets underway - Fierce Biotech
googlenews
Feb 9, 2023
New hires
external-link
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement - GlobeNewswire
googlenews
May 3, 2023
Science/business updates
external-link
Magenta to explore sale, merger after study setback - BioPharma Dive
googlenews
Feb 3, 2023
Science/business updates
external-link
Top 40+ startups in Hematopoietic Stem Cell Therapy in Nov, 2024 - Tracxn
googlenews
Nov 25, 2024
Science/business updates
external-link
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
crunchbase
Jun 8, 2020
Science/business updates
external-link
Vertex plunks down $950M for stem cell player Semma Therapeutics - Fierce Biotech
googlenews
Sep 3, 2019
Funding-related
external-link
(DNTH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
googlenews
Dec 20, 2024
Science/business updates
external-link
Trend Tracker for (DNTH) - Stock Traders Daily
googlenews
Dec 9, 2024
Science/business updates
external-link
Magenta Therapeutics exercises ATAC licence option - European Biotechnology News
googlenews
Nov 13, 2019
Science/business updates
external-link
Foundation Medicine’s Jason Ryan signs on as Magenta CFO, COO - Fierce Biotech
googlenews
Nov 19, 2018
New hires
external-link
Magenta Therapeutics (MGTA) Stock Price, News & Analysis - MarketBeat
googlenews
Jun 28, 2018
Science/business updates
external-link
Magenta to explore strategic alternatives after patient’s death in Phase 1/2 - PPF Group
googlenews
Jul 22, 2023
Science/business updates
external-link
Magenta gains $50M Series B, Novartis candidate and ...
fiercebiotech.com
Dec 19, 2024
Funding-related
external-link
Magenta Cuts 5 Executives, 84% of Staff Following Patient Death - BioSpace
googlenews
Feb 3, 2023
New hires
external-link
Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
crunchbase
Feb 25, 2019
Science/business updates
external-link
Pfizer’s John Davis splashes into biotech as Magenta CMO - Fierce Biotech
googlenews
Feb 21, 2018
New hires
external-link
Magenta Therapeutics Cuts Workforce by 14%, Shifts Focus to R&D
crunchbase
Apr 14, 2022
New hires
external-link
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell
googlenews
Dec 4, 2020
Science/business updates
external-link
Magenta Therapeutics: Q1 Earnings Insights
crunchbase
May 16, 2022
Science/business updates
external-link
Magenta Therapeutics starts trading on the NASDAQ
crunchbase
Jun 21, 2018
Funding-related
external-link
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
crunchbase
Feb 25, 2019
Science/business updates
external-link
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors - Business Wire
googlenews
Jul 7, 2021
New hires
external-link
MGTA-456 Earns Regenerative Medicine Advanced Therapy Designation - Adrenoleukodystrophy News
googlenews
Sep 24, 2019
Science/business updates
external-link
Semma names former Novartis, Magenta executive as new CEO - Fierce Biotech
googlenews
May 10, 2018
New hires
external-link
Hedge Funds Have Never Been This Bullish On Magenta Therapeutics, Inc. (MGTA) - Yahoo Finance
googlenews
Oct 7, 2020
Funding-related
external-link
FDA tells Magenta to pump the brakes on blood cancer trial ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
Magenta CSO Michael Cooke jumps to IFM Therapeutics - Fierce Biotech
googlenews
Jan 7, 2020
New hires
external-link
After dose de-escalation, death drives Magenta to pause antibody-drug conjugate leukemia trial - Fierce Biotech
googlenews
Jan 26, 2023
Science/business updates
external-link
Magenta Therapeutics Voluntarily Stops Phase 1/2 Study of ADC MGTA-117 Due to Serious Adverse Event - OncoZine
googlenews
Feb 11, 2023
Science/business updates
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com